Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
Democratic Rep. Maxine Waters on Tuesday requested that Facebook pause its development of Libra, an upcoming cryptocurrency that the company plans to release in 2020.Technologyread more
Tesla loses vice president of HR and head of diversity, Felicia Mayo, one of a few black woman executives to break Silicon Valley's glass ceiling.Technologyread more
Union Pacific CEO Lance Fritz tells Jim Cramer that he is optimistic about trade relations with China, Mexico, Japan, and the EU.Mad Money with Jim Cramerread more
The S&P 500 is closing in on its all-time high, and is likely to sail past it, as long as the Fed promises lower interest rates and the trade war calms down.Market Insiderread more
American Airlines pilots plan to tell lawmakers they are still concerned about fixes to grounded Boeing 737 Max planes.Airlinesread more
"I do expect our stock market to be hammered if nothing positive comes of this G-20 meeting ... the most likely outcome is nothing happens," Jim Cramer says.Mad Money with Jim Cramerread more
See which stocks are posting big moves after the bell on June 18.Market Insiderread more
President Donald Trump on Tuesday announced that he will not nominate acting Defense Secretary Patrick Shanahan to hold the position in a permanent capacity. Army Secretary...Politicsread more
But a look at state-by-state data clarifies the scale of Trump's challenge. As the president tries to rally supporters at a 2020 kickoff rally in Orlando on Tuesday, he is...Politicsread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
The Food and Drug Administration is proposing a rule for breast cancer screenings that would require doctors to give women more information about the risks associated with dense breasts.
The agency wants doctors to ensure patients understand how dense breasts, which don't have a lot of fatty tissue, can skew the accuracy of mammograms and present a higher risk of developing breast cancer later in life. About 12 percent of all women are diagnosed with breast cancer at some point in their life, the FDA said, citing data from the National Cancer Institute.
"Given that more than half of women over the age of 40 in the U.S. have dense breasts, helping to ensure patient access to information about the impact that breast density and other factors can have on the risk for developing breast cancer is an important part of a comprehensive breast health strategy," FDA Principal Deputy Commissioner Amy Abernethy said in a statement Wednesday.
Mammograms are considered the best way to detect breast cancer. However, they're not as reliable in dense breasts, characterized as those with not as much fat and more fibrous or glandular tissue, according to the American Cancer Society. Dense tissue makes it harder for doctors to see cancer, meaning the tests can be less accurate.
"Mammograms of dense breasts ... can be difficult to interpret because the dense tissue can obscure signs of breast cancer and lower the sensitivity of the image," the FDA said. "Dense breasts have also been identified as a risk factor for developing breast cancer."
The FDA is proposing specific language to explain how density may skew the results and to encourage women to talk to their doctor about how this relates to cancer risk and their individual situation.
The agency also wants to tighten its regulation of mammography facilities, including with the ability to notify patients that testing did not meet the FDA's quality standards. The rule will be open for public comments for the next 90 days.
"We're certainly imposing additional and stronger requirements on these facilities," the FDA's Dr. Jeff Shuren told reporters on a conference call Wednesday "We think this is important to protect the public health and best serve patients."
Currently, 37 states require some sort of notification to women with dense breasts, according advocacy group DenseBreast-Info. If implemented, the FDA's language would set the national standard, though states could pursue more stringent requirements, said Shuren, the agency's director of the Center for Devices and Radiological Health.
He outlined the specific language that women with dense breasts would receive:
"Mammography is the best screening test to search for breast cancer, but it does not find all breast cancers. Some patients have high breast tissue density, more glands than fat in the breasts, which makes it harder to find breast cancer on a mammogram. Your breast tissue density is high. Some patients with high breast density may need other imaging tests in addition to mammograms. Follow the recommendations in this letter and talk to your health care provider about high breast density and how it relates to breast cancer risk and your individual situation."
"Generally, we're really pleased to see the FDA has taken the important step to empower women to make informed decisions about their health," said Caroline Powers, director of federal relations at the American Cancer Society Cancer Action Network.
Powers said the group has pushed the FDA on the issue for several years. Regardless of momentum at the state level, the organization wanted a federal standard to make sure women around the country were receiving the same information.